We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-17.28%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$222M
AUM Growth
-$86.4M
Cap. Flow
-$22.6M
Cap. Flow %
-10.18%
Top 10 Hldgs %
33.77%
Holding
109
New
40
Increased
8
Reduced
21
Closed
35

Top Buys

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$11.9M
2
AMGN icon
Amgen
AMGN
+$7.88M
3
GILD icon
Gilead Sciences
GILD
+$7.77M
4
CELG
Celgene Corp
CELG
+$7.45M
5
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$6.84M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$12.1M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10M
3
ENDP
Endo International plc
ENDP
+$9.56M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$9.04M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.41M

Sector Composition

Rank Sector Weight
1 Healthcare 82.57%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADVM
76
CALL
DELISTED
Adverum Biotechnologies
ADVM
– –
-15,000
Closed -$2.44M
ADVM
77
DELISTED
Adverum Biotechnologies
ADVM
– –
-1,500
Closed -$244K
ALNY icon
78
Alnylam Pharmaceuticals
ALNY
$37.8B
– –
-90,000
Closed -$10M
ASMB icon
79
Assembly Biosciences
ASMB
$512M
– –
-14,583
Closed -$3.37M
BIIB icon
80
Biogen
BIIB
$30.8B
– –
-30,000
Closed -$12.1M
CI icon
81
Cigna
CI
$75.1B
– –
-37,500
Closed -$6.08M
DXCM icon
82
DexCom
DXCM
$30.1B
– –
-260,000
Closed -$5.2M
ELV icon
83
Elevance Health
ELV
$80.9B
– –
-20,000
Closed -$3.28M
ESPR
84
DELISTED
Esperion Therapeutics
ESPR
– –
-75,000
Closed -$6.13M
FOLD
85
DELISTED
Amicus Therapeutics
FOLD
– –
-375,000
Closed -$5.31M
GKOS icon
86
Glaukos
GKOS
$9.13B
– –
-15,000
Closed -$435K
IRWD icon
87
Ironwood Pharmaceuticals
IRWD
$637M
– –
-417,900
Closed -$4.22M
PTCT icon
88
PTC Therapeutics
PTCT
$6.51B
– –
-100,000
Closed -$4.28M
RMTI icon
89
CALL
Rockwell Medical
RMTI
$22.6M
– –
-1,818
Closed -$3.22M
SAGE
90
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-31,700
Closed -$2.31M
TXMD icon
91
TherapeuticsMD
TXMD
$23.6M
– –
-8,000
Closed -$2.84M
VNDA icon
92
Vanda Pharmaceuticals
VNDA
$328M
– –
-350,000
Closed -$4.44M
VRTX icon
93
Vertex Pharmaceuticals
VRTX
$123B
– –
-60,000
Closed -$7.41M
XENE icon
94
Xenon Pharmaceuticals
XENE
$6.47B
– –
-37,500
Closed -$432K
XOMA
95
DELISTED
Xoma
XOMA
– –
-6,250
Closed -$485K
ZVRA icon
96
Zevra Therapeutics
ZVRA
$754M
– –
-10,938
Closed -$3.21M
ALPN
97
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-12,500
Closed -$758K
ARAV
98
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-16,667
Closed -$1.52M
SIOX
99
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-16,875
Closed -$2.75M
ENDP
100
DELISTED
Endo International plc
ENDP
– –
-120,000
Closed -$9.56M
1 2 3
4
5

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Ghost Tree Capital held 109 positions worth $222M, down 28% from $309M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ghost Tree Capital withdrew a net $22.6M in Q3 2015, closing 35 positions and reducing 21 holdings. Its most notable exit was Biogen, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier, followed by Financials.

Against the trend, Ghost Tree Capital opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $7.67M.

  • Ghost Tree Capital's largest Q3 2015 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 120,000 shares worth $7.67M.
  • Ghost Tree Capital added most to ZELTIQ Aesthetics, Inc. in Q3 2015, an estimated $2.81M increase.
  • Ghost Tree Capital's biggest Q3 2015 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $7M.
  • Ghost Tree Capital fully exited Biogen in Q3 2015, selling an estimated $12.1M.
  • Ghost Tree Capital's ten largest holdings make up 34% of its $222M portfolio in Q3 2015.
  • Ghost Tree Capital opened 40 new positions and closed 35 in Q3 2015.
  • Ghost Tree Capital's portfolio value fell 28% quarter-over-quarter to $222M.

Based on Ghost Tree Capital's 13F filing for Q3 2015, filed 16 Nov 2015.